The World's Second Approved Biosimilars of Denosumab (MAILISHU)
SHANGHAI,April 3,2023 --Mabwell (688062.SH),an innovative biopharmaceutical company with the layout of whole industry chain,announced that the Denosumab solution for injection (trade name: MAILISHU,project code: 9MW0311),which is developed by its wholly-owned subsidiary T-mab,has been formally approved for marketing by the National Medical Products Administration (NMPA) (Approval No.: S20233111).
MAILISHU is the world's second approved Biosimilars of Denosumab for the osteoporosis in postmenopausal women at high risk of fracture. The drug can significantly reduce the risk of vertebral,non-vertebral and hip fractures within this patient segment.
The Marketing Center of Mabwell has mapped MAILISHU's launched plan since Q4,2022 and optimizingcontinuously product promotion strategies and resource allocation plans by researching on the treatment field,patient composition,market potential and other aspects. It is expected that more than 200 hospitals will be accessed and sales goal will not be less than 300K units.
Dr. Datao Liu,co-founder & CEO of Mabwell said,"We're so excited to announce MAILISHU has been approved. It's our 2nd commercialized.Age related diseases are Mabwell's priority areas. More than half of the Chinese aged women suffer from osteoporosis,and fragility fractures,a complication of osteoporosis,are a major risk of life quality and life safety for patients. Mabwell has formed a professional marketing & sales team to take efforts to improve domestic patients' accessibility in China. In addition,We have reached strategic collaborations in global market and hope to work with overseas partners to benefit more osteoporosis patients worldwide.
About Mabwell
Mabwell (688062.SH),an innovation-driven biopharmaceutical company,has the whole industrial chain of R&D,manufacturing,and commercialization. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017,an advanced R&D system which covers target discovery,early discovery,druggability,preclinical,clinical research and manufacturing transformation was established. Mabwell has 17 pipeline products in different R&D stages based on a world-class and state-of-the-art R&D engine,including 13 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of auto-immune diseases,oncology,metabolic disorders,ophthalmologic diseases and infectious diseases,etc. Of these,2 products have been approved and commercialized,1 product has been filed for MA approval,3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development",2 projects for National Key R&D Programmes,and several provincial and municipal science and technological innovation projects. Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA,FDA and EMA,and has passed the EU QP Audit. The large-scale manufacturing base located in Shanghai is under construction. Our mission is "Explore Life,Benefit Health" and our vision is "Innovation,from ideas to reality". For more information,please visit www.mabwell.com.
Forward-Looking Statements
This press release contains forward-looking statements including,but not limited to,the potential safety,efficacy,regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development,clinical studies,clinical and regulatory milestones and timelines,market opportunity,competitive position,possible or assumed future results of operations,business strategies,potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties,which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions,including,"expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.
Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks,uncertainties,and other factors,many of which are beyond the Company's control,but not limited to:environment; politic; economy; society; legislation; our dependence on our product candidates,most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors,such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate,or any assumptions are incorrect,the actual results may be seriously inconsistent with the stated results.
The Company cautions all the persons not to place undue reliance on any such forward-looking statements,which speaks only as of the date of this press release. The Company disclaims any obligation,except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events,conditions,or circumstances on which any such statements may be based,or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions,figures and assumptions in this press release are applicable to this statement.
